Taking medicines from bench to bedside : comparemela.com

The ongoing review of the EU Pharmaceutical Legislation is looking at recalibrating IP incentives. Intellectual Property fuels medical innovations from the research bench to the patient’s bedside.

Related Keywords

New York , United States , Corey Dow Hygelund , Davidw Thomas , Justin Burns , John Audette , Madam Carroll , Biotechnology Innovation Organization , Charles River Associates Oct , New York Times , Therapeutics Development , Clinical Development Success , Faculty Of Pharmaceutical Sciences Ghent University , Thomas De Beer , Pharmaceutical Sciences , Ghent University , Last Accessed Nov , Clinical Development Success Rates , Golden Age , Biotechnology , Clinical Trials , Data , Drug And Device Safety , Evolution Of Health Care , Health Care , Hospitals , Innovation , Intellectual Property , Investment , Major And Chronic Diseases , Markets , Medicines , Patents , Patient Access , Patients , Policy , Regulatory , Research , Research And Development , Safety , Technology , Transparency ,